Piper Sandler on Aclaris Therapeutis (ACRS): 'Efficacy Differentiation Could Drive Share Re-Rate'
Piper Sandler analyst Biren Amin reiterated an Overweight rating and $11.00 price target on Aclaris Therapeutis (NASDAQ: ACRS).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)